U.S., Oct. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07205861) titled 'Retrospective Epidemiological Study of Patients in the National Cohort of the French TMA Center' on Sept. 25.
Brief Summary: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening disorder characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and ischemic organ damage due to microvascular thrombosis. It results from a severe deficiency in the von Willeband factor (vWF)-cleaving protease ADAMTS13, primarily caused by autoantibodies that inhibit its activity. This deficiency leads to accumulation of ultra-large vWF multimers, triggering pathological platelet aggregation and widespread micro...